Cejemly (sugemalimab) is a fully human, immunoglobin G4 monoclonal antibody immune checkpoint inhibitor (ICI), which binds to programmed cell death ligand (PDL1).
Access our deep dive into this approval - in a useful, downloadable PDF format.
Read Now
Sign up to our monthly newsletter. Our newsletter gives you the latest European and UK regulatory intelligence. We bring you new and interesting approvals; fast-to-market applications, orphan designations; paediatric applications and therapy area-specific news.
You can unsubscribe at any time from the link in the newsletter footer. Read our Privacy Policy here.